U.S. scientists are studying the mechanisms of a rare neurological disorder, called familial dysautonomia, with the aid of induced pluripotent stem cells -- in this case, derived from the reprogrammed skin cells of patients with the disease. They also are using the iPS cells to test the effectiveness of several drug candidates on the rare condition.

Related Summaries